A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus

Journal of Zhejiang University: Science B

Volumn 15, Issue 6, 2014, Pages 575-581

  Ruszkowska Ciastek, Barbara ^a   Sokup, Alina ^a   Socha, Maciej W ^a   Ruprecht, Zofia ^a   Hałas, Lidia ^a   Góralczyk, Barbara ^a   Góralczyk, Krzysztof ^a   Gadomska, Grazyna ^a   Rość, Danuta ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Angiogenesis; Glycated hemoglobin (HbA1c); Lipid abnormalities; Type 2 Diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; METABOLISM; MIDDLE AGED; PILOT STUDY;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84904045993     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1400024     Document Type: Article

References (26)

1. Araszkiewicz, A., Zozulińska, D., Wierusz-Wysocka, B., 2004. Assessment of vascular-endothelial growth factor (VEGF) serum concentration in type 1 diabetic subject. Diabet. Dosw. Klin., 4(S3):197-201 (in Polish).
2. Barańska, P., Jerczyńska, H., Pawłowska, Z., 2005. Vascular endothelial growth factor-structure and functions. Postepy Biochem., 51(1):12-21 (in Polish).
3. Basha, B., Samuel, S.M., Triggle, C.R., et al., 2012. Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress? Exp. Diabetes Res., 2012:481840. [doi:10.1155/2012/481840]
4. Cameron, N.E., Eaton, S.E.M., Cotter, M.A., 2001. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 44(11):1973-1988. [doi:10.1007/s001250100001] (Pubitemid 33124042)
5. Cooper, M., Vranes, D., Youssef, S., et al., 1999. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes, 48(11):2229-2238. [doi:10.2337/diabetes.48. 11.2229]
6. Derzhko, R., Witkowska, M., 2006. Glucose metabolism disturbances and the risk of cardiovascular diseases. Adv. Clin. Exp. Med., 15(5):911-916. (Pubitemid 44823288)
7. Gumbrecht, J., 2004. Insulin and endothelium. Przew. Lek., 7:58-61 (in Polish).
8. International Diabetes Federation, 2012. Diabetes Atlas, 5th Ed. Brussels, Belgium.
9. Janota, J., Pomyje, J., Toth, D., et al., 2003. Expression of angiopoietic factors in normal and type-I diabetes human placenta: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol., 111(2):153-156. [doi:10.1016/S0301-2115(03)00 204-5] (Pubitemid 37338733)
10. Jansson, P.A., 2007. Endothelial dysfunction in insulin resistance and type 2 diabetes. J. Intern. Med., 262(2): 173-183. [doi:10.1111/j.1365-2796. 2007.01830.x]
11. Kieć-Wilk, B., Dudek, W., Dembińska-Kieć, A., 2006. Nutrigenomics, angiogenesis and obesity. Acta Angiol., 12(4):141-148. (Pubitemid 46438751)
12. Kim, H.N., Oh, H.J., Seo, A.J., et al., 2005. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int., 67(1):167- 177. [doi:10.1111/j.1523-1755.2005.00067.x]
13. Kowalski, J., Śliwczyńska-Rodziewicz, D., Kowalczyk, E., et al., 2011. Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications. Pol. Merkur. Lekarski, 30(178):249-252 (in Polish).
14. Kubisz, P., Chudy, P., Staśko, J., et al., 2010. Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus. Acta Diabetol., 47(2):119-124. [doi:10.1007/s00592-009-0127-2]
15. Mahdy, R.A., Nada, W.M., Hadhoud, K.M., et al., 2010. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye, 24(10):1576-1584. [doi:10.1038/eye.2010.86]
16. Olokoba, A.B., Obateru, O.A., Olokoba, L.B., 2012. Type 2 diabetes mellitus: a review of current trends. Oman Med. J., 27(4):269-273. [doi:10.5001/omj.2012.68]
17. Pacholczyk, M., Ferenc, T., Kowalski, J., 2008. The metabolic syndrome. Part II: its mechanisms of development and its complications. Postepy Hig. Med. Dosw., 62:543-558 (in Polish).
18. Peczyńska, J., Urban, M., Urban, B., et al., 2004. Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy. Endokrynol. Diabetol. Chor. Przemiany Materii Wieku Rozw., 10(1):41-48 (in Polish). (Pubitemid 39023815)
19. Santilli, F., Spagnoli, A., Mohn, A., 2001. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J. Clin. Endocrinol. Metab., 86(8):3871. [doi:10. 1210/jcem.86.8.7752]
20. Skóra, J., Biegus, J., Pupka, A., et al., 2006. Molecular basics of angiogenesis. Postepy Hig. Med. Dosw., 60:410-415 (in Polish).
21. Stuttfeld, E., Ballmer-Hofer, K., 2009. Structure and function of VEGF receptors. IUBMB Life, 61(9):915-922. [doi:10. 1002/iub.234]
22. Swidzińska, E., Naumnik, W., Chyczewska, E., 2006. Angiogenesis and neoangiogenesis - the role in lung cancer and other tumors. Pneumonol. Alergol. Pol., 74(4):414-420 (in Polish).
23. Wada, H., Ura, S., Kitajka, S., et al., 2011. Distinct characteristics of circulating vascular endothelial growth factor-A and C levels in human subjects. PLoS ONE, 6(12):e29351. [doi:10.1371/journal.pone.0029351]
24. Witmer, A.N., Blaauwgeers, H.G., Weich, H.A., et al., 2002. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest. Ophthalmol. Vis. Sci., 43(3): 849-857. (Pubitemid 34184506)
25. World Health Organization, 2011. Global Status Report on Noncommunicable Diseases 2010. Available from http://www.who.int/nmh/publications/ncd-report- full-en.pdf
26. Zielonka, T.M., 2004. Angiogenesis. Part II. Factors that modulate the process of formation of new blood vessels. Alergy Asthma Immunol., 9(1):25-31.